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Abstract Bisphenol A (BPA) is a monomer used mainly
in the synthesis of polycarbonates and epoxy resins. Per-
cutaneous absorption is the second source of exposure,
after inhalation, in the work environment. However, studies
on this route of absorption are lacking or incomplete. In
this study, percutaneous BPA absorption was measured in
vivo and ex vivo in the rat, and ex vivo in humans. An
approximately 12-fold difference in permeability between
rat skin and human skin was found, with permeability
being higher in the rat. In addition, inter- and intra-indi-
vidual variability of up to tenfold was observed in humans.
No accumulation of BPA in the skin was found during
exposure. The skin clearance rate following exposure was
estimated at 0.4 lg/cm
2/h. Ex vivo and in vivo percuta-
neous absorption ﬂuxes of BPA in the rat were in the same
range (about 2.0 lg/cm
2/h), suggesting that extrapolation
to the in vivo situation in humans may be possible. The
European tolerable daily intake (TDI) of BPA is 50 lg/kg
body weight. However, many research projects have
highlighted the signiﬁcant effects of BPA in rodents at
doses lower than 10 lg/kg/day. A 1-h occupational expo-
sure over 2,000 cm
2 (forearms and hands) may lead to a
BPA absorption of 4 lg/kg/day. This is 8% of the Euro-
pean TDI and is very close to the value at which effects
have been observed in animals. This absorption must
therefore be taken into account when evaluating risks of
BPA exposure, at least until more relevant results on the
toxicity of BPA in humans are available.
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Abbreviations
BPA Bisphenol A
CERHR Center for evaluation of risks to human
reproduction
EFSA European food safety authority
HPLC High performance liquid chromatography
LOAEL Lowest observed adverse effect level
NTP National toxicology program
TDI Tolerable daily intake
TEWL Trans-epidermal water loss
Introduction
Bisphenol A (BPA, CAS No. 80-05-7) is a plastic mono-
mer and plasticizer, primarily used in the production of
polycarbonate plastics and epoxy resins. It is one of the
world’s highest production-volume chemicals, with more
than 2 million metric tons produced worldwide in 2003. A
6–10% yearly growth in demand for BPA is predicted
(Burridge 2003). In its assessment of the risks associated
with BPA, published in January 2007, the European Food
Safety Authority (EFSA) set a full tolerable daily intake
(TDI) of 50 lg/kg body weight/day. In March 2010, EFSA
received a request from the European Commission to take
into account in its risk assessment any other new scientiﬁc
evidence that may be available and to review scientiﬁc
arguments supplied by Denmark in support of the gov-
ernment’s decision to ban the use of BPA in food contact
materials for infants aged from 0 to 3 years. EFSA updated
its advice on BPA in September 2010. Only in vivo studies
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for the purpose of this risk assessment in order to assess the
validity and/or applicability of the individual ﬁndings to
human risk assessment. They concluded that following a
detailed and comprehensive review of recent scientiﬁc
literature on the toxicity of BPA at low doses, they could
not identify any new evidence that would lead them to
revise the current TDI for BPA of 50 lg/kg body weight
set in its 2006 opinion and re-conﬁrmed in its 2008
opinion.
Following oral dosing in humans, BPA was rapidly
conjugated and excreted in urine due to the absence of
enterohepatic circulation (Vo ¨lkel et al. 2002). In the same
way, BPA given orally or intravenously to cynomolgus
monkeys was also mainly excreted in urine (Kurebayashi
et al. 2002). In contrast, after oral or intravenous admin-
istration in rats, the major excretion route was feces
(Kurebayashi et al. 2003; Domoradzki et al. 2003), sug-
gesting that BPA is mainly metabolized to BPA-glucuro-
nide and excreted into feces through the bile and subject
to enterohepatic circulation in rats, irrespective of dose
and administration route. In December 2004, vom Saal
and Hughes (2005) reviewed 115 published studies that
used low doses of BPA, below the previous lowest
observed adverse effect level (LOAEL) of 50 lg/kg/day.
In vivo estrogenic activity of BPA was reported in 94 of
the studies reviewed, and 31 reported effects caused by
doses of BPA at or below the reference dose of 50 lg/kg/
day. Many of the adverse effects observed (sexual matu-
ration, hormone levels in blood, fertility, immune func-
tion, enzyme activity, brain chemistry, behavior, etc.)
were due to exposure during early development (gestation
and/or lactation), but effects due to exposure postweaning,
right up to adulthood, have been reported (Al-Hiyasat
et al. 2002; Palanza et al. 2002; Rubin et al. 2001). Se-
kizawa (2008) reported that adverse effects on develop-
ment, reproduction, morphology, behavior, and sexual
dimorphism were observed in rats and mice at doses
below 10 lg/kg/day. Based on human samples, Vo ¨lkel
et al. (2008) determined an average urinary concentration
of 2.5 lg/l and used this value for risk assessment. The
authors then determined total BPA in 147 urine samples
and found concentrations between \LOD (0.3 lg/l) and
9.3 lg/l. In another study carried out in the United States,
Calafat et al. (2005) measured urinary BPA in a reference
population of 394 adults. BPA concentrations C 0.1 lg/l
were detected in 95% of the samples examined, with
geometric mean and median concentrations of 1.33 and
1.28 lg/l, respectively. In a more recent study, high uri-
nary BPA concentrations were associated with cardio-
vascular diagnoses, diabetes, and clinically abnormal
concentrations of the liver enzymes c-glutamyltransferase
and alkaline phosphatase (Lang et al. 2008). Thus, most
humans are exposed to BPA at sufﬁcient levels for it to be
detectable in the urine and high urinary concentrations
have been linked to various diseases.
In the United States, the National Toxicology Program
(NTP) Center for the Evaluation of Risks to Human
Reproduction (CERHR) evaluated the potential for BPA to
cause adverse effects on reproduction and development in
humans (NTP-CEHRH 2008). The NTP concluded that
there were some concerns about the effects on the brain,
behavior, and prostate gland in fetuses, infants, and chil-
dren, at current levels of human exposure to BPA. How-
ever, they also concluded that current levels of human
exposure to bisphenol A in fetuses, infants, and children
were of minimal concern for effects on the mammary gland
and an earlier age for puberty in females. In addition, they
expressed minimal concern that exposure to BPA at higher
levels in occupational settings would cause reproductive
effects in workers. At the end of 2008, the National Insti-
tute of Environmental Health Sciences (NIEHS) and NTP
published a request for information (RFI) on their website,
seeking input on a number of key research areas identiﬁed
in recent evaluations of BPA. This should help focus future
research and testing of BPA.
It is commonly assumed that human exposure to
chemical toxicants occurs mainly through breathing, but
toxic materials used in the workplace can often result in
absorption through the skin. Despite the growing interest of
regulatory authorities for BPA effects on organisms, data
on percutaneous absorption of BPA are almost impossible
to obtain. To our knowledge, there is only one study that
quantiﬁes the transcutaneous penetration of BPA in pig
skin (Kaddar et al. 2008). Unfortunately, the results of
Kaddar et al.’s study do not allow an absorption ﬂux for
BPA to be calculated.
The aim of the present study was to determine the
percutaneous absorption ﬂux for BPA. First of all, using
complementary techniques, the absorption ﬂux was deter-
mined in vivo and ex vivo in male Sprague–Dawley rats.
Then, human skin samples were exposed ex vivo to BPA in
the same conditions as those used for rats. Results from the
two species were then compared with a view to extrapo-
lating from the ex vivo ﬂuxes to reﬂect what happens in
human skin in situ.
Materials and methods
Test and control substances
Radiolabeled bisphenol A ([ring
14C(U)]-bisphenol A) was
supplied by Moravek Biochemicals, Inc. (California, USA)
with a speciﬁc radioactivity of 7.4 GBq/mmol (200 mCi/
mmol). Radiochemical purity, as determined by the
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was stored at -20C. The working solutions were prepared
1 day before their administration, by weighing [
14C]-BPA,
unlabeled BPA (Sigma–Aldrich Chimie Sarl, Saint Quentin
Fallavier, France) and vehicle with a precision balance,
veriﬁed as part of a quality assurance process. A radio-
chemical purity control was performed on each working
solution by HPLC after dilution of the stock solution.
Liquid scintillation (Tri-Carb 2900TR, Perkin Elmer, the
Netherlands) was used to determine radiochemical con-
centration on triplicate samples. Unlabeled BPA chemical
purity, as indicated by the supplier, was more than 99%.
The unlabeled compound was stored in an amber bottle at
room temperature. All other chemicals and materials were
from Sigma–Aldrich, unless speciﬁed, and were of the
highest available purity.
Animals
Sprague–Dawley male rats (Charles River, Saint Germain
sur L’Arbresle, France) weighing 250–300 g were used for
the in vivo studies. The animals were kept at constant
temperature and humidity with free access to a commercial
rodent diet (food pellets, Scientiﬁc Animal Food and
Engineering, Augy, France). Animals were acclimatized to
the laboratory conditions for at least 4 days before the start
of experiments.
Mass balance after intravenous administration
of [
14C]-BPA
[
14C]-BPA was administered intravenously in a 10%
CremophorEL
solution(1 ml/kg)intothedorsalveinofthe
penis of lightly isoﬂurane anaesthetized rats. The doses
tested were 10, 50, 100, 500, and 1,000 lg/kg of BPA
(n = 3–6). Precise individual doses were determined by
weighing the syringe before and after each injection. The
radiocarbon dose was about 0.7 MBq/kg (20 lCi/kg). After
injection,theanimalswereimmediatelyplacedinindividual
metabolism cages for urine and feces collection. Urine was
collected at 4, 8, 24, 30, 48, and 72 h. Feces were collected
every 24 h. At the end of the experiment, the animals were
euthanized by a lethal intravenous injection of sodium pen-
tobarbital (CEVA SANTE ANIMALE, France), under light
isoﬂurane anesthesia. The remaining radioactivity was
determined after digesting carcasses in an alcohol/KOH
mixture (1.5 M, H2O/ethanol, V/V, 1/4).
In vivo percutaneous penetration and absorption
of BPA
One day before administration, hair was clipped in the
shoulder and back region. On the day of administration the
skin surface was gently wiped with acetone to remove
sebum. The surface to be exposed (10 cm
2) was delimited
by gluing an aluminum ring onto the clipped area with
cyanoacrylate glue (Loctite, Senlis, France). The experi-
ments were performed with [
14C]-BPA dissolved in ace-
tone (4 mg BPA/ml, 50 ll/cm
2). Individual doses were
determined by weighing the syringe before and after each
deposit. The acetone was allowed to evaporate and the ring
was covered with a Tedlar
 membrane for occlusion. The
radiocarbon dose was about 0.7 MBq/kg (20 lCi/kg).
Immediately after BPA application, the animals were
placed in metabolism cages for urine and feces collection.
Batches of 3–5 rats were euthanatized after different
exposure times (1–30 h). At the end of the exposure period,
the skin around the ring was washed with a swab humid-
iﬁed with ethanol to detect any leakage of BPA outside the
treated site. Ethanol (500 ll) was introduced through the
Tedlar
 membrane to dissolve the remaining surface BPA.
The membrane was then cut and the non-absorbed fraction
of BPA at the application site removed. The skin was dried
with cotton swabs, which were scintillation counted sepa-
rately. The radioactivity content was measured in the fol-
lowing samples: plasma, exposed skin, skin around the
exposure site, ring ? membrane, swabs, urine, feces (for
24 and 30 h of exposure), and carcass.
Ex vivo percutaneous absorption of BPA in rats
and humans
Ex vivo percutaneous absorption was assessed using static
Franz diffusion cells with fresh full thickness or derma-
tomed rat skin or human skin samples. Rats were killed by
intra-peritoneal injection of a lethal dose of sodium pen-
tobarbital. The entire dorsal region was clipped and the
subcutaneous tissue carefully removed. Human skin sam-
ples were obtained from patients undergoing plastic sur-
gery. The skin was cut into circular sections (1.76 cm
2) and
placed in diffusion cells with the stratum corneum facing
up. Skin thickness was measured with a plate thickness
gauge (Prost-Bourillon, Lune ´ville, France). Diffusion cells
were maintained at a temperature of 36C with a circu-
lating water bath, which yielded a skin surface temperature
of 32 ± 1C. The dermis side was kept in contact with the
receptor ﬂuid (RPMI, 2% BSA, 1% penicillin/streptomy-
cin), which had been previously ﬁltered through a sterile
Millex
 0.22-lm-pore-size ﬁlter and degassed with a
vacuum pump. The solubility of BPA in this receptor ﬂuid
is at least 300 lg/ml. [
14C]-BPA in acetone (4 mg BPA/ml)
was applied to the skin (50 ll/cm
2 and 200 lg/cm
2) for
24 h. An aliquot of receptor ﬂuid was collected regularly
over the 24-h period with an automatic fraction collector
(Gilson FC 204, Middleton, WI, USA). The volume of
receptor ﬂuid was maintained at a constant level by adding
Arch Toxicol (2011) 85:1035–1043 1037
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matically. At the end of the experiment, the unabsorbed
dose of [
14C]-BPA was removed from the skin surface with
ethanol and dry cotton swabs, as described for the in vivo
experiments. The skin was digested in an 80% ethanol
solution of KOH (1.5 M). Total radioactivity in the various
fractions was determined by direct liquid scintillation
counting.
The integrity of each skin sample was assessed before
performing permeation experiments by the measurement of
trans-epidermal water loss (TEWL), one of the three
methods recommended by the OECD (guidance 28, 2004).
TEWL measurements have the advantage that no solutions
have to be added to perform the barrier integrity test other
than those used in the permeation experiments. Samples
with a TEWL value higher than 13 g/m
2/h were discarded.
The rate of metabolism of water-soluble tetrazolium salt
(WST) into formazan was used to evaluate cellular via-
bility. A non-viable skin control was obtained by freezing
samples for 1 h at -20C.
HPLC analysis of urinary BPA by ﬂuorescence
BPA and its metabolites (glucuronides and/or sulfonides)
were analyzed by HPLC according to the method devel-
oped by Matsumoto et al. (2003). Urine (100 ll) was
buffered with 50 ll of 0.01 M sodium acetate buffer (pH
5.0) and hydrolyzed enzymatically with 5 llo fb-glucu-
ronidase/sulfatase using Helix pomatia (Merck, Darmstadt,
Germany), for 18 h at 37C. After hydrolysis, 445 llo f
acetonitrile was added to the hydrolysate and it was placed
for 15 min at -20C. After centrifugation for 10 min at
20,000g, 300 ll of the supernatant was transferred to a new
tube and 200 ll of 0.01 M sodium acetate buffer (pH 2.7)
was added. The solution (100 ll) was injected onto the
HPLC system.
The HPLC system (Varian) consisted of a 9012 pump
system operating at 1.0 ml/min ﬂowrate; the mobile phase
was prepared by mixing 0.01 M sodium acetate buffer (pH
2.7) and acetonitrile (65:35) in the isocratic mode; a 410
autosampler, which injected 100 ll of the processed sam-
ple into the system; a Waters Spherisorb
 ODS2 5-lm
column (4.6 mm inner diameter 9 250 mm length); a
Prostar 363 ﬂuorescence detector (excitation 275 nm/
emission 300 nm).
Data reporting
Statistic analysis was performed with Statgraphics software
(Sigma Plus, Toulouse, France). Values were expressed as
mean ± SD. ANOVA followed by a Dunett’s test was used
to determine statistical signiﬁcance. The level of signiﬁ-
cance was set at P\0.05.
The percentage in vivo absorption was calculated using
the radioactivity content in excreta and carcass, as follows:
Absorbed dose (% )¼% of applied dose recovered in urine
þfecesþcarcass ð1Þ
Percentage penetration was calculated using the
radioactivity content in excreta, carcass, and exposed skin
area:
Penetrated dose (% ) ¼ absorbed dose (% )
þ % of applied dose recovered in exposed skin area
ð2Þ
Absorption ﬂux and penetration ﬂux, expressed in lg/h/
cm
2 were calculated from the slope of the cumulative curve
of the absorbed and penetrated doses as a function of time
(Fig. 1), respectively.
The lag time (Tlag) was calculated as the intercept of the
steady state portion of the curve on the time axis.
The percentage of the absorbed dose ex vivo was cal-
culated from the radioactivity content detected in the
receptor ﬂuid:
Absorbed dose (% )
¼ % of applied dose recovered in receptor fluid ð3Þ
The absorption ﬂux Fmax, expressed in lg/cm
2/h, is the
maximum absorption ﬂux determined during exposure.
Estimation of the absorbed dose in the workplace:
Q ¼
F   T   S
M
ð4Þ
where Q is the daily absorbed quantity (lg/kg), F the
absorption ﬂux (lg/cm
2/h), T the exposure time (h), S the
exposed surface (cm
2), and M the body weight (kg).
Results
Mass balance of [
14C]-BPA after intravenous
administration
The [
14C] mass balance after a single intravenous admin-
istration of different doses of [
14C]-BPA is presented in
Table 1. Regardless of the dose administered, the per-
centages of [
14C] excreted in feces and urine were not
signiﬁcantly different, indicating no saturation of the
excretion pathway. The total recovery was in the range
90–101% of the administered dose. The apparent urinary
excretion half-life calculated from the 50 and 500 lg/kg
doses was 9.9 ± 2.1 h.
[
14C] was predominantly excreted in feces, which
accounted for about 63–75% of the excretion over the 72-h
period. Within this period, urinary excretion accounted for
1038 Arch Toxicol (2011) 85:1035–1043
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14C] and occurred
essentially in the ﬁrst 24 h after administration. After this
period, [
14C] was principally excreted in feces.
In vivo percutaneous absorption of BPA
The cumulative percutaneous absorption and penetration of
[
14C]-BPA are shown in Fig. 1. The absorbed (Eq. 1) and
penetrated (Eq. 2) doses increased linearly with exposure
time. The penetration and absorption ﬂuxes, calculated
from the cumulative curves of penetrated and absorbed
doses as a function of time, were identical (2.5 ± 0.2 lg/
cm
2/h). Penetration ﬂux was maximal after 1 h of expo-
sure. The calculated lag times were not signiﬁcantly dif-
ferent from zero.
BPA penetrated rapidly into the skin (Table 2). Skin
content was not signiﬁcantly different throughout exposure
time (mean value was 31 ± 10 lg/cm
2), indicating no
accumulation of BPA in the skin. [
14C] excreted in feces
was three- to sixfold higher than in urine for an exposition
time of 24 or 30 h. The total recovery was in the range of
90–100% of the administered dose.
The skin BPA content was measured either at the end of
an 8-h percutaneous exposure or 64 h after an 8-h exposure
was 33.0 ± 6.0 and 6.2 ± 2.2 lg/cm
2, respectively. Over
this time period, the absorbed dose increased from
25 ± 8 lg/cm
2 (8 h exposure) to 46 ± 7 lg/cm
2 (64 h
later).
Ex vivo percutaneous absorption of BPA
Effect on integrity and viability
The effect of BPA on the integrity and viability of the skin
was evaluated (Table 3). After exposure to 200 lg/cm
2
BPA for 24 h, viability and integrity of the tested samples
were not signiﬁcantly different from control samples
(viable skin without BPA).
Cutaneous metabolism of BPA
BPA may be metabolized as it passes through the skin, and
the extent of this metabolism was estimated by measuring
BPA metabolites in the ﬂuid receptor after 24-h exposure
to BPA (200 lg/cm
2) on fresh dermatomed rat and human
skin samples. For both human and rat skin, unmodiﬁed
BPA accounted for more than 97% of the radioactivity
detected in the receptor ﬂuid (Table 4).
Human/rat comparison
Results from humans and rats were compared for percu-
taneous exposure to [
14C]-BPA on dermatomed skin sam-
ples (thickness about 0.4 mm) (Table 5). The percutaneous
absorption ﬂux (Fmax) measured on human skin was about
tenfold lower than the ﬂux measured on rat skin.
Discussion
Bisphenol A is a widely used monomer with established
estrogenic properties. The objective of this study was to
determine in vivo and ex vivo percutaneous absorption
ﬂuxes for BPA in rats and to see how these results could be
extrapolated to humans.
After intravenous administration of increasing doses of
[
14C]-BPA (from 10 to 1,000 lg/kg), the mass balance
showed that [
14C] was predominantly excreted in feces
(63–74% of the administered dose). From the ﬁve doses
tested, no signiﬁcant difference was found in terms of
excreted quantities of [
14C] in feces and urine as a function
of the doses administered. Thus, there was no saturation of
the BPA excretion pathway. The urinary excretion half-life
Fig. 1 In vivo cumulative percutaneous penetration and absorption
of [
14C]-BPA in male Sprague–Dawley rats. Batches of rats were
euthanatized at different times after a topical exposure to [
14C]-BPA
under occlusion. [
14C]-BPA was dissolved at 4 mg/ml in acetone,
50 ll/cm
2, corresponding to a dose of 200 lg of BPA/cm
2 were
applied to the skin over a 10 cm
2 area. Acetone was allowed to
evaporate. Values are expressed as mean ± SD. Cumulative pene-
tration (ﬁlled square) and absorption (open circle) versus time are
plotted. Penetration ﬂux: F1( lg/cm
2/h) = 2.6 (±0.2), r = 0.97.
Absorption ﬂux: F2( lg/cm
2/h) = 2.5 (±0.2), r = 0.98. Tlag is not
signiﬁcantly different from 0 for either curve
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9.9 ± 2.1 h. Urinary excretion accounted for between 12
and 22% of the administered dose and occurred principally
within the ﬁrst 24 h post-dosing. Previous reports had also
indicated that about 80–90% of the urinary [
14C] was
excreted during the ﬁrst 24 h (Kurebayashi et al. 2003).
Table 1 Mass balance of [
14C] after intravenous administration of different doses of [
14C]-BPA in male Sprague–Dawley rats
Dose (lg/kg) 10 50
a 100 500 1,000
n 53 565
Urine
0–4 h 10.4 (2.4) 2.97 (0.16)* 7.73 (5.62) 4.48 (2.93) 7.65 (4.95)
4–8 h 5.23 (0.95) 1.76 (0.37) 4.43 (2.90) 1.67 (0.95) 5.14 (2.59)
8–24 h 4.47 (1.61) 4.90 (1.27) 4.13 (1.62) 4.60 (1.84) 5.30 (1.69)
24–48 h 1.19 (0.28) 2.14 (0.87) 1.26 (0.51) 2.25 (0.67) 2.02 (0.70)
48–72 h 0.35 (0.08) – 0.42 (0.37) 0.71 (0.18) 0.87 (0.65)
Total urine 21.6 (3.8) 11.8 (2.5) 18.0 (9.1) 13.7 (6.2) 21.0 (5.1)
Feces
0–24 h 34.3 (4.7) 42.3 (3.3) 39.6 (6.6) 33.9 (7.7) 25.8 (14.7)
24–48 h 25.0 (3.1) 28.8 (6.6) 24.0 (9.0) 27.8 (3.0) 28.8 (3.5)
48–72 h 5.9 (0.6) – 7.3 (2.8) 11.8 (3.9) 8.5 (3.7)
Total feces 65.4 (3.3) 71.1 (5.3) 70.9 (9.7) 73.5 (6.5) 63.1 (11.9)
Carcass 3.32 (0.80) 18.6 (5.3)** 3.52 (1.79) 6.44 (1.77) 8.35 (5.74)
Recovery 90.4 (1.9) 101 (4)** 92.3 (3.3) 93.6 (1.1) 92.4 (3.8)
Values are expressed as a percentage of the dose administered ± SD [mean (SD)]
[
14C]-BPA was administered intravenously in a 10% Cremophor
 solution (1 ml/kg) into the dorsal vein of the penis of lightly anesthetized rats.
The radiocarbon dose was about 0.7 MBq/kg. Statistical analysis: ANOVA followed by Dunett’s test: * P\0.05; ** P\0.01 (10 lg/kg dose
was used as reference group)
a Animals were euthanized 48 h after IV administration (72 h for the other groups)
Table 2 Mass balance of [
14C] after topical administration of [
14C]-BPA in male Sprague–Dawley rats
Exposure time (h) 1 2 4 8 24 30 8
Sacriﬁce time (h) 1 2 4 8 24 30 72
n 557581 1 5
Urine 0–4 h
a 0.01 (0.01) 0.03 (0.01) 0.03 (0.03) 0.03 (0.01) 0.05 (0.04) 0.07 (0.04) 0.06 (0.04)
Urine 4–8
a 0.26 (0.15) 0.14 (0.06) 0.19 (0.08) 0.24 (0.14)
Urine 8–24 h
a 1.55 (1.75) 1.38 (0.43) 0.92 (0.64)
Urine 24–30 h
a 0.62 (0.36) 0.22 (0.10)
Total urine
a 0.01 (0.01) 0.03 (0.01) 0.03 (0.03) 0.29 (0.16) 1.74 (1.82) 2.27 (0.76) 2.56 (1.07)
Total feces
a 6.28 (2.92) 9.97 (2.66) 16.4 (1.9)
Carcass
a 0.73 (0.13) 2.00 (0.38) 2.80 (1.77) 12.2 (4.1) 18.6 (7.4) 26.3 (4.2) 4.30 (1.89)
Exposed skin
a 11.3 (1.8) 13.8 (2.9) 19.2 (4.0) 16.5 (3.1) 19.7 (5.1) 12.7 (3.6) 3.09 (1.09)
Surrounding skin
a 0.25 (0.11) 0.17 (0.09) 0.29 (0.35) 0.14 (0.04) 0.21 (0.11) 0.38 (0.54) 0.06 (0.05)
Unabsorbed dose
a 82.4 (2.1) 79.1 (3.2) 71.6 (3.2) 69.5 (3.8) 48.2 (5.7) 43.7 (4.1) 68.2 (3.7)
[
14C] Recovery
a 94.7 (0.7) 95.1 (0.6) 93.9 (0.8) 98.6 (0.6) 94.8 (3.5) 95.3 (2.6) 94.7 (1.2)
Absorbed dose
a 0.77 (0.13) 2.03 (0.38) 2.82 (1.79) 12.5 (4.3) 26.6 (9.8) 38.6 (3.5) 23.3 (3.5)
Penetrated dose
a 12.3 (1.8) 16.0 (3.1) 22.3 (2.8) 29.1 (3.4) 46.6 (6.2) 51.6 (4.8) 26.4 (2.8)
Absorption ﬂux
b 1.53 (0.26) 2.03 (0.38) 1.41 (0.90) 3.12 (1.07) 2.22 (0.82) 2.65 (0.26) ND
Penetration ﬂux
b 24.6 (3.7) 16.0 (3.1) 11.2 (1.40) 7.28 (0.86) 3.88 (0.52) 3.44 (0.32) ND
Batches of male Sprague–Dawley rats were euthanized at different times after topical exposure to [
14C]-BPA under occlusion (4 mg/ml in
acetone, which was evaporated, 50 ll/cm
2, 200 lg of BPA/cm
2,1 0c m
2). The radiocarbon dose was about 0.7 MBq/kg
ND not determined
a Measured values expressed as a percentage of the dose administered ± SD [mean (SD)]
b Calculated ﬂuxes expressed in lg/cm
2/h ± SD [mean (SD)]
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14C]-BPA in rats, 78
and 13% of the administered dose were recovered in feces
and urine, respectively, within the ﬁrst 48 h.
Using the data from rats, illustrating cumulative curves
of penetrated and absorbed doses over time, the percuta-
neous ﬂuxes for penetration and absorption were found to
be identical (2.5 ± 0.2 lg/cm
2/h). Moreover, the skin
content did not change signiﬁcantly between 1 and 30 h, or
at any time during exposure, with a mean value of
31 ± 10 lg/cm
2. These results indicated that throughout
exposure, there was no accumulation of BPA in the skin.
Thus, under the conditions used in this study, BPA pene-
trated rapidly into the skin and the maximal penetration
ﬂux was obtained after 1 h of exposure. Sixty-four hours
after an 8-h exposure, the skin content decreased from 33
to 6 lg/cm
2. Over the same time period, the calculated
absorbed dose increased from 25 to 46 lg/cm
2. These
results showed that the BPA present in skin at the end of
exposure is available for diffusion and absorption. Thus,
the skin constituted a reservoir for BPA. This skin reservoir
effect after the end of exposure to BPA may explain the
increase in the urinary half-life for the excretion of
14C
compared with the i.v. route (28 and 10 h, respectively). It
has also been demonstrated that the skin acts as a reservoir
for several other molecules such as corticosteroids (Vickers
1963) and lipophilic compounds (Kemppainen et al. 1992;
Payan et al. 2001). In particular, a two-fold increase in
urinary T1/2 was found for pyrene when comparing i.v. and
trans-cutaneous routes (Payan et al. 2008).
In order to examine a possible toxic effect of BPA on
the skin, viability and physical integrity of skin samples
were measured ex vivo after 24-h exposure to 200 lg/cm
2
BPA. Trans-epidermal water loss (TEWL), which mea-
sures the skin’s barrier function, and WST colorimetric
assay for cell viability, which reﬂects mitochondrial
activity, were not signiﬁcantly different in test and control
samples. At the studied dose, BPA was therefore not
considered to be cytotoxic for the skin and did not affect
the skin’s integrity.
Prior to their passage through the skin, some molecules
have to be metabolized (Hewitt et al. 2000; Payan et al.
2001, 2008, 2009; Zhang et al. 2009). The receptor ﬂuids
of rat and human viable skin exposed for 24 h to BPA were
analyzed by HPLC to establish their metabolic proﬁles.
Under our conditions, for both rats and humans, unmodi-
ﬁed BPA accounted for more than 97% of the radioactivity
found in the receptor ﬂuid, suggesting that BPA was not
metabolized during its skin transfer. In contrast, Zalko
et al. (2010) concluded in a recent study that BPA was
efﬁciently absorbed and metabolized in short-term culture
of viable pig ear skin and human explants. The major
metabolites produced were BPA mono-glucuronide and
BPA mono-sulfate. However, skin viability did not sig-
niﬁcantly modify the absorption rate of BPA. Indeed, the
percentages of radioactivity recovered in the culture media
were 65.3 ± 8.2% and 58.1 ± 3.6% respectively, for
Table 3 Effect of bisphenol A on skin integrity and viability
BPA
(lg/cm
2)
Skin
state
Physical
integrity
(TEWL)
Viability of
skin cells
(WST test)
0 Viable 132 (28) 121 (36)
0 Non-viable 145 (5) 21 (5)*
200 Viable 113 (12) 80 (21)
Values are expressed as a percentage of initial value ± SD [mean
(SD)], n = 3
TEWL and WST viability were compared before and after exposure
to 200 lg/cm
2 BPA for 24 h. Non-viable skin was prepared by
freezing fresh skin for 1 h at -20C. TEWL trans-epidermal water
loss. WST test evaluates the ability of the skin to metabolize tetra-
zolium salts to produce formazan, reﬂecting mitochondrial activity.
Statistical analysis: ANOVA followed by Dunett’s t test: * P\0.05
(non-exposed viable skin as reference group)
Table 4 BPA metabolite proﬁle in receptor ﬂuid after percutaneous
administration of [
14C]-BPA
Rat Human
n 67
BPA 97.5 (0.5) 97.5 (2.4)
BPA-gluc 2.1 (0.7) \LOD
Others 0.4 (0.5) 2.5 (2.4)
Values are expressed as percentages of total
14C ± SD [mean (SD)].
Human: 4 donors with 1 or 2 samples/donor. Rats: 3 animals with 2
samples/animal
After exposing rat and human viable skin to 200 lg/cm
2 bisphenol A
for 24 h, the levels of unchanged BPA and its metabolites were
determined in receptor ﬂuid by HPLC
LOD limit of detection (1.5 ng/ml under our analyzing conditions),
BPA unchanged BPA, BPA-gluc BPA glucuro-conjugated metabolites
Table 5 Human/rat ex vivo comparison after percutaneous admin-
istration of [
14C]-BPA on dermatomed frozen skin
Rat Human
n 91 5
Thickness (mm) 0.46 (0.04) 0.50 (0.12)
Fmax (lg/cm
2/h) 1.48 (0.41) 0.12 (0.09)
Tmax (h) 7.3 (2.6) 23.5 (1.4)
F20–24 h (lg/cm
2/h) 0.96 (0.23) 0.11 (0.07)
Recovery (% Q0) 93.5 (2.3) 96.5 (1.9)
Values are expressed as percentages of dose applied ± SD [mean
(SD)]. Human: 6 donors in duplicate or triplicate. Rat: 6 rats with 1 or
2 samples/rat
Comparison of absorption ﬂuxes after exposing rat and human skin ex
vivo to 200 lg/cm
2 of BPA for 24 h. Skin samples were obtained
from six different donors for each species (1–3 samples for each)
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were conﬁrmed by the comparison of absorption kinetics
carried out ex vivo on rat skin using fresh (viable) and
frozen (non-viable and no metabolic activity) skin samples.
The Fmax values measured, 1.7 ± 0.5 and 2.1 ± 0.4 lg/
cm
2/h for viable and non-viable skin respectively, were not
signiﬁcantly different.
Using frozen human dermatomed skin samples about
400 lm thick, the measured Fmax was about tenfold lower
than that for the rat under the same exposure conditions
(1.48 ± 0.41 lg/cm
2/h for rat vs. 0.12 ± 0.09 lg/cm
2/h
for human). A similar difference in skin permeability
between human and rat was previously reported for the
percutaneous passage of BPA diglycidyl ether (BADGE)
on dermatomed fresh skin (Boogaard et al. 2000). For
BPA, a signiﬁcant level of intra- and inter-individual var-
iability was observed with human skin samples, varying up
to tenfold. In a multi-center comparative study, conducted
in vitro with three different products on human skin sam-
ples, van de Sandt et al. (2004) showed a similar level of
variation, which they attributed to differences in human
skin samples.
In the rat, extrapolation of the ex vivo results obtained
with dermatomed skin samples (about 500 lm of thick-
ness) to model what happens in vivo may be possible.
Indeed, the Fmax-measured ex vivo (1.48 lg/cm
2/h) was
relatively close to the in vivo value (2.5 lg/cm
2/h). If we
allow a similar extrapolation for human skin, it becomes
possible to give an estimate of occupational cutaneous
exposure to BPA. Considering a 1-h exposure over
2,000 cm
2, representing the forearms and the hands,
(ECETOC 1993) and using the normally assumed 60 kg
body weight, percutaneous absorbed BPA would be about
4 lg/kg/day (Eq. 4). In a recent study, Biedermann et al.
(2010) evaluated a possible BPA transfer from thermal
printing paper (containing 8–17 g/kg of BPA) to the fore-
ﬁnger and the middle ﬁnger. The obtained results lead the
authors to estimate at 71 lg/day the potential exposure of a
person repeatedly touching this type of paper for 10 h/day.
These two results represent approximately 2–10% of the
present TDI, but are not so far from the value for which
adverse effects were observed in animal experiments.
Evaporation from the skin may limit the degree of expo-
sition in occupational exposures and act like a barrier
against toxicants. In the case of bisphenol A, Biedermann
et al. (2010) concluded that the BPA transferred to the
foreﬁnger and the middle ﬁnger could be ten times more if
these ﬁngers were wet or very greasy, suggesting that
evaporation could enhance the BPA skin absorption.
Experiment conducted ex vivo in the rats with or without
occlusion showed that under our experimental conditions,
there were no signiﬁcant differences for the ﬂuxes mea-
sured in both conditions (data not shown).
In conclusion, BPA penetrated rapidly into the skin and
was not at all or only very slightly metabolized during its
passage through the skin. In vivo and ex vivo absorption
ﬂuxes measured using rat skin were similar and thus per-
mitted an extrapolation of human in vivo values based on
ex vivo results obtained on dermatomed skin. The esti-
mated in vivo value of 4 lg/kg/day is not so far from the
dose for which adverse effects have been observed in some
experiments in rats and mice. Thus, this value must be
taken into account when evaluating risks related to BPA
exposure, at least until more relevant results on the toxicity
of BPA in humans are available.
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